Literature DB >> 9989500

Backbone mutations in transmembrane domains of a ligand-gated ion channel: implications for the mechanism of gating.

P M England1, Y Zhang, D A Dougherty, H A Lester.   

Abstract

An approach to identify backbone conformational changes underlying nicotinic acetylcholine receptor (nAChR) gating was developed. Specific backbone peptide bonds were replaced with an ester, which disrupts backbone hydrogen bonds at the site of mutation. At a conserved proline residue (alphaPro221) in the first transmembrane (M1) domain, the amide-to-ester mutation provides receptors with near-normal sensitivity, although the natural amino acids tested other than Pro produce receptors that gate with a much larger EC50 than normal. Therefore, a backbone hydrogen bond at this site may interfere with normal gating. In the alphaM2 domain, the amide-to-ester mutation yielded functional receptors at 15 positions, 3 of which provided receptors with >10-fold lower EC50 than wild type. These results support a model for gating that includes significant changes of backbone conformation within the M2 domain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989500     DOI: 10.1016/s0092-8674(00)80962-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  39 in total

1.  Conformation-dependent hydrophobic photolabeling of the nicotinic receptor: electrophysiology-coordinated photochemistry and mass spectrometry.

Authors:  John F Leite; Michael P Blanton; Mona Shahgholi; Dennis A Dougherty; Henry A Lester
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

2.  One-microsecond molecular dynamics simulation of channel gating in a nicotinic receptor homologue.

Authors:  Hugues Nury; Frédéric Poitevin; Catherine Van Renterghem; Jean-Pierre Changeux; Pierre-Jean Corringer; Marc Delarue; Marc Baaden
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

3.  Barbiturates require the N terminus and first transmembrane domain of the delta subunit for enhancement of alpha1beta3delta GABAA receptor currents.

Authors:  Hua-Jun Feng; Robert L Macdonald
Journal:  J Biol Chem       Date:  2010-06-04       Impact factor: 5.157

4.  Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH.

Authors:  Angela P Blum; Henry A Lester; Dennis A Dougherty
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

5.  Atomistic insights into human Cys-loop receptors by solution NMR.

Authors:  David D Mowrey; Monica N Kinde; Yan Xu; Pei Tang
Journal:  Biochim Biophys Acta       Date:  2014-03-28

6.  Open-channel structures of the human glycine receptor α1 full-length transmembrane domain.

Authors:  David D Mowrey; Tanxing Cui; Yuanyuan Jia; Dejian Ma; Alexander M Makhov; Peijun Zhang; Pei Tang; Yan Xu
Journal:  Structure       Date:  2013-08-29       Impact factor: 5.006

7.  Key roles of hydrophobic rings of TM2 in gating of the alpha9alpha10 nicotinic cholinergic receptor.

Authors:  Paola V Plazas; María J De Rosa; María E Gomez-Casati; Miguel Verbitsky; Noelia Weisstaub; Eleonora Katz; Cecilia Bouzat; Ana Belén Elgoyhen
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 8.  Incorporation of Non-Canonical Amino Acids.

Authors:  Lilia Leisle; Francis Valiyaveetil; Ryan A Mehl; Christopher A Ahern
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

9.  An intersubunit hydrogen bond in the nicotinic acetylcholine receptor that contributes to channel gating.

Authors:  Kristin Rule Gleitsman; Sean M A Kedrowski; Henry A Lester; Dennis A Dougherty
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

10.  A selenide-based approach to photochemical cleavage of peptide and protein backbones at engineered backbone esters.

Authors:  Amy L Eastwood; Angela P Blum; Niki M Zacharias; Dennis A Dougherty
Journal:  J Org Chem       Date:  2009-12-04       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.